ORIC

Oric Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

10.230

+0.2(1.994%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.255

Open

10.060

VWAP

10.11

Vol

711.54K

Mkt Cap

993.57M

Low

9.870

Amount

7.19M

EV/EBITDA(TTM)

Total Shares

67.42M

589.33M

EV/OCF(TTM)

P/S(TTM)

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.366

-12.86%

-0.369

-27.58%

-0.392

-20%

Estimates Revision

Stock Price

Go Up

+20.78%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 18.00 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.230

Low

12.00

Averages

18.00

High

23.00

Current: 10.230

Low

12.00

Averages

18.00

High

23.00

H.C. Wainwright

Buy

downgrade

$22 -> $19

2025-08-14

Reason

H.C. Wainwright

Price Target

$22 -> $19

2025-08-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Oric Pharmaceuticals to $19 from $22 and keeps a Buy rating on the shares following the Q2 report.

Ladenburg

NULL -> Buy

initiated

$15

2025-07-08

Reason

Ladenburg

Price Target

$15

2025-07-08

initiated

NULL -> Buy

Reason

Ladenburg initiated coverage of Oric Pharmaceuticals with a Buy rating and $15 price target. The firm cites the emerging profile of ORIC-944 as \"a potential fast-follower to mevrometostat\" as well as the strategic pivot for development of ORIC-114 from second-line to the first-line, which represents a larger addressable population and opportunity.

JPMorgan

analyst

Strong Buy

maintain

$20

2025-05-29

Reason

JPMorgan

analyst

Price Target

$20

2025-05-29

maintain

Strong Buy

Reason

JPMorgan views Oric Pharmaceuticals' Phase 1b dose-escalation combination data for ORIC-944 plus AR inhibitor in metastatic castration-resistant prostate cancer as a "home run scenario." The early ORIC-944 combination data "hits our home run scenario," with clear signals of better PSA responses and better safety relative to the known data from the Xtandi plus mevrometostat update, the analyst tells investors in a research note. JPMorgan views Oric shares as "significantly undervalued" and sees potential to for the stock to "grind to mid-teens to high-teens with time." It keeps an Overweight rating on Oric with a $20 price target.

H.C. Wainwright

Buy

maintain

$21 -> $22

2025-05-09

Reason

H.C. Wainwright

Price Target

$21 -> $22

2025-05-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Oric Pharmaceuticals to $22 from $21 and keeps a Buy rating on the shares following the Q1 report.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$21

2025-02-26

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$21

2025-02-26

Reiterates

Strong Buy

Reason

JP Morgan

Anupam Rama

Buy

Maintains

$21 → $22

2025-02-26

Reason

JP Morgan

Anupam Rama

Price Target

$21 → $22

2025-02-26

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Oric Pharmaceuticals Inc (ORIC.O) is -6.79, compared to its 5-year average forward P/E of -5.74. For a more detailed relative valuation and DCF analysis to assess Oric Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.74

Current PE

-6.79

Overvalued PE

-1.71

Undervalued PE

-9.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.32

Current EV/EBITDA

-4.69

Overvalued EV/EBITDA

0.66

Undervalued EV/EBITDA

-7.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00